13 – 15 October 2026
Hall 1, Messe Basel

Discovery • Development • Clinical Trials • Manufacturing • Market Access • Fill & Finish


Mark Chiu
President | Tavotek Biotherapeutics


I'm speaking at Festival of Biologics Basel 2026.


Join my session:

  • Trispecific EGFR x cMET x VEGF Antibody, TAVO412, has Clinical Responses in colorectal, Esophageal and Lung Cancers

EUROPE'S LARGEST BIOLOGICS EVENT

 3,000

Attendees

350

Speakers

150

Exhibitors

100

Start- Ups

3

Days

About Festival of Biologics

 

The Festival of Biologics Basel is Europe’s largest biologics event, covering the start-to-finish of the industry in antibody therapies, cell and gene therapies, immunotherapies and biosimilars. Designed for industry experts in pharma and biotech, start-ups, academics, regulators and investors, the Festival of Biologics is the meeting place for the large molecule therapy ecosystem, bringing together 3000+ attendees.
 
Join 350 world class speakers in exploring the latest research in early stage discovery, modality engineering, translational medicine, clinical trials, manufacturing, commercialisation and fill/finish operations across key therapy and disease areas. With three days of presentations, panels, roundtables and workshops, this event is the place to be to keep up with the latest advances across the entire biologics and ATMP value chain.

What is the Festival of Biologics?

Conference

The start to finish of biologic drug development from discovery through to market access across 3 days and 13 tracks

Exhibition

150 leading solution providers to meet your needs across discovery, development, manufacturing, fill finish and market access

Networking

Connect with thousands of biologics experts in 12+ hours of built-in 1-2-1 networking

The start-to-finish of biologics

Content Themes

DISEASE AREAS
Oncology
Chronic and acute inflammation
Autoimmune diseases
Infectious diseases
Neurodegenerative diseases
THERAPIES
Antibody formats (mAbs, Bispecifics, ADCs)
Cell therapy
Gene therapy
Vaccines
Precision medicine
Checkpoint inhibition
Combination therapies
Biosimilars
DISCOVERY
Protein expression & discovery
Target identification
Lead screening
Optimisation methods
Antibody expression
AI for discovery
DEVELOPMENT
Protein engineering
Gene engineering
Analytics
Immunogenicity
AI and computational tools
CMC
Biomarkers
Tumor Microenvironment
Biosimilars
CLINICAL TRIALS OPERATIONS
Trial design
Patient recruitment
Digital/data systems
Site selection
Regulation
Real world evidence
AI
Wearables
MANUFACTURING
Upstream processing
Downstream processing
Formulation
Purification
Cell line development
Biosimilar manufacturing
FILL & FINISH AND LOGISTICS
Injectables
Aseptic fill
Freeze drying
Shipping systems
Global and local supply chain management
FINANCE AND INVESTMENT
Seed investment
Licensing
Mergers and acquisitions
VC and accelerator funding
Global investment landscape
COMMERCIALISATION AND MARKET ACCESS
Get to market
Regulatory environment
Biosimilar commercialisation
Market sustainability
DIAGNOSTICS
Companion Diagnostics
Molecular Diagnostics
Biomarker Analysis
In Vivo Techniques
Diagnostic Devices

Join us in Basel
13 - 15 October
Hall 1.0 Messe Basel

REGISTER NOW